



Giles, Timothy and Yon, Lisa and Hannant, Duncan and Barrow, Paul and Abu-Median, Abu-Bakr (2015) Development of a DNA-based microarray for the detection of zoonotic pathogens in rodent species. *Molecular and Cellular Probes*, 29 (6). pp. 427-437. ISSN 1096-1194

**Access from the University of Nottingham repository:**

<http://eprints.nottingham.ac.uk/38439/1/Microarray%20development%20manuscript%20text.pdf>

**Copyright and reuse:**

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the Creative Commons Attribution Non-commercial No Derivatives licence and may be reused according to the conditions of the licence. For more details see: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

**A note on versions:**

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact [eprints@nottingham.ac.uk](mailto:eprints@nottingham.ac.uk)

1 Development of a DNA-based Microarray for the Detection of Zoonotic Pathogens in Rodent  
2 Species

3 Giles, Timothy<sup>1</sup>; Yon, Lisa<sup>1</sup>; de Bree, Freddy<sup>2</sup>; Bossers, Alex<sup>2</sup>; Hannant, Duncan<sup>1</sup>; Barrow,  
4 Paul<sup>1</sup>; Abu-Median, Abu-Bakr<sup>1</sup>.

5 <sup>1</sup>University of Nottingham, Nottingham, United Kingdom

6 <sup>2</sup> Central Veterinary Institute, Wageningen University and Research Centre, The Netherlands

7 Abstract

8

9 The demand for diagnostic tools that allow simultaneous screening of samples for multiple  
10 pathogens is increasing because they overcome the limitations of other methods, which can  
11 only screen for a single or a few pathogens at a time. Microarrays offer the advantages of  
12 being capable to test a large number of samples simultaneously, screening for multiple  
13 pathogen types per sample and having comparable sensitivity to existing methods such as  
14 PCR. Array design is often considered the most important process in any microarray  
15 experiment and can be the deciding factor in the success of a study. There are currently no  
16 microarrays for simultaneous detection of rodent-borne pathogens. The aim of this report is  
17 to explicate the design, development and evaluation of a microarray platform for use as a  
18 screening tool that combines ease of use and rapid identification of a number of rodent-borne  
19 pathogens of zoonotic importance. Nucleic acid was amplified by multiplex biotinylation  
20 PCR prior to hybridisation onto microarrays. The array sensitivity was comparable to  
21 standard PCR, though less sensitive than real-time PCR. The array presented here is a  
22 prototype microarray identification system for zoonotic pathogens that can infect rodent  
23 species.

24 Keywords

25 Microarray, Development, Rodent, Zoonoses, ArrayTube, ArrayStrip

26

27

## 28 Highlights

- 29 • We have developed a microarray to detect zoonotic pathogens in rodent species.
- 30 • The design stage of a microarray experiment is crucial for a successful experiment.
- 31 • We examined the difference between amplification methods prior to hybridisation.

## 32 1.1 Introduction

33

34 Prompt detection of pathogens is a significant issue in diagnostic testing for both human and  
35 veterinary health. This is particularly relevant when slow-growing or fastidious organisms  
36 are involved and the limitations of some existing diagnostic tools are driving researchers to  
37 consider alternative methods, as demands on quantity and rapidity of testing methods are  
38 increasing [1]. Serological methods provide an indication of exposure to a pathogen and are  
39 best used for screening populations. However, they also require an adequate time post-  
40 infection/exposure for antibodies to develop and may be unable to distinguish between  
41 different strains or antigenic types of pathogen. Zoonotic pathogens make up the majority  
42 (75%) of emerging diseases and wildlife are a major source of these pathogens [2]. Early  
43 detection of pathogens in wild animals would be useful in identifying risk factors associated  
44 with disease transmission to humans or domestic animals, and this could help prevent a  
45 possible outbreak. It has also been suggested that prevention of disease, which could be  
46 aided by an effective surveillance system, is better than reacting to an outbreak, or to finding  
47 a cure [3]. Microarrays offer the advantage of testing large numbers of samples  
48 simultaneously, coupled with screening a single sample for multiple pathogens. Use of this  
49 technology would enable timely, accurate and inexpensive detection of pathogens, which  
50 could lead to more effective control of these infectious diseases, which has positive  
51 implications for public health [4]. There are a wide ranging number of potential applications  
52 for pathogen detection arrays; and have been used for the detection of novel pathogens, as in  
53 the case of severe acute respiratory syndrome (SARS) [5], simultaneous detection of

54 Newcastle disease virus and avian influenza virus in birds [6] and detection of viruses that  
55 can cause vesicular or vesicular-like lesions in livestock [7].

56 Although microarrays are used widely, the fluorescence-based glass slide arrays are relatively  
57 expensive. Alternatives to the glass slide microarray are the ArrayTube™ (AT) and  
58 ArrayStrip™ (AS) platforms from Alere Technologies GmbH (Jena, Germany). These are  
59 much less expensive, and can be used without highly specialised equipment [8]. The AT (up  
60 to 225 spots) and AS (up to 600 spots per well) platforms make the use of a small array  
61 surface of size 4 x 4 mm placed on the bottom of a plastic vial or well. Hybridisation and  
62 analysis are simple and rapid, using standard laboratory methods, and hybridisation signals  
63 are detected following an enzyme-catalysed precipitation reaction [9]. The use of plastic  
64 tube-integrated arrays and fast non-fluorescent labelling and hybridisation protocols results in  
65 a system that is cost-effective, time saving, and allows high sample throughput, in a 96 well  
66 format [1].

67 There are currently no microarrays for the detection of multiple rodent-borne pathogens. The  
68 aim of this report is to explicate the design, development and evaluation of a microarray  
69 platform for use as a screening tool, which combines ease of use and rapid identification of a  
70 number of rodent-borne pathogens of zoonotic importance.

## 71 2.1 Materials and Methods

### 72 2.1.1. Probe design

73 An initial literature search was performed to identify zoonotic pathogens which are  
74 transmissible by rodents. A microarray was then developed to screen for the presence of  
75 these pathogens. Table 1 shows the list of pathogens to be screened for, including the source  
76 of any reference material if available. Unfortunately, not all of the pathogens for which the  
77 array was designed to detect could be sourced. Therefore the probes for, Hepatitis E Virus,  
78 *Bartonella*, MRSA, *R. typhi* and *S. monilliformis* were not evaluated. RNA from an infected

79 *Rattus norvegicus* sample was supplied but several attempts at PCR proved unsuccessful and  
80 it was concluded that the RNA had degraded too much to be of use. A further literature  
81 search was conducted to identify particular genes or target regions which had been previously  
82 used for identification purposes in other diagnostic tests such as PCR. The DNA sequences  
83 were obtained from the NCBI database and aligned using ClustalX2  
84 ([http://www.ebi.ac.uk/Tools/phylogeny/clustalW2\\_phylogeny/help/faq.html#5](http://www.ebi.ac.uk/Tools/phylogeny/clustalW2_phylogeny/help/faq.html#5)) software.  
85 Oligonucleotide sequences (probes) were designed for each pathogen from regions targeted  
86 by species-specific or generic primers. Two freely available software packages were used for  
87 probe design: Unique Probe Selector (UPS) [10] and OligoWiz [11, 12]. Both types of  
88 software were used to compensate for any limitations in the other. OligoWiz, at present, can  
89 only be used to design probes for bacteria.  
90 An optimal length of 60-nucleotide probes was assigned, and parameters for both OligoWiz  
91 and UPS included cross-hybridisation, delta-T<sub>m</sub>, low-complexity, position and folding. An  
92 *in silico* analysis was performed on all the probes using the BLAST tool on the NCBI  
93 database to determine if cross-hybridisation would occur with any other known sequences.  
94 The selected probes were synthesised at Metabion International (Jena, Germany) with the  
95 following specifications: NH<sub>2</sub> modification at the 3' end, no modification at the 5' end,  
96 purification with HPLC, 0.04 μmol scale, and absolutely biotin-free.  
97 The AT platform was used for initial evaluation for individual pathogens, and the best  
98 performing probes were transferred to the AS platform making a pool of probes from  
99 different pathogens. For both platforms, each probe was directly spotted onto the array  
100 surface at a 15 μM concentration with each probe printed in duplicate.

101

102 2.1.2. Primer design

103 Generic primers were designed from conserved flanking regions of the target sequence using  
104 Primer3 (<http://primer3.ut.ee/>). Species-specific primers were designed from more variable  
105 regions of a sequence that were specific to certain pathogens. The amplicon size was set  
106 between 250 and 750 bases, with an optimum of 500 bases. Primer sequences for both  
107 multiplex PCR and real-time PCR can be seen in Table 2.

108 Table 1.

109 A list of all the reference materials that were available for this study.

110 Table 2.

111

112 Primers used during the evaluation of the arrays. The majority were designed during the  
113 study but others were obtained either from the literature or colleagues.

114

### 115 2.1.3. Nucleic acid amplification

116 Several amplification methods were tested including sequence-independent amplification  
117 [13] using a random pentadecamer primer and a primer tag, and sequence-dependent  
118 amplification using pathogen-specific primers.

119

#### 120 2.1.3.1. Sequence-independent amplification

121 Any RNA present in the sample was reverse transcribed into cDNA with 1.0 µl of primer A  
122 (GTT TCC CAG TCA CGA TCN NNN NNN NNN NNN NN) (40 µM), 1.0 µl of 10mM  
123 dNTP mix (Invitrogen), and variable amounts of water and template (minimum 50 ng/µl)  
124 were mixed in a PCR tube to a total volume of 13µl. The volume of water was variable to  
125 allow for different concentrations of template. This was then heated to 65°C for five min  
126 using a thermal cycler. The mixture was placed on ice for at least one minute. A separate  
127 mixture containing 4.0 µl of 5x Reverse Transcriptase Buffer (Invitrogen), 1.0 µl of 0.1M  
128 Dithiothreitol (DTT) (Invitrogen), 1.0 µl of RNase inhibitor, RNaseOUT (Invitrogen), and  
129 1.0 µl of SuperScript III Reverse Transcriptase (Invitrogen) was added to the PCR tube

130 contents, and mixed by pipetting. The 20  $\mu$ l reaction was incubated using a thermal cycler at  
131 25°C for five min, then at 50°C for one hour and finally at 70°C for 15 min to inactivate the  
132 reaction. The reaction was left at room temperature for five min, followed by one minute on  
133 ice. The mix was then heated to 94 °C for two min, and rapidly cooled to 10°C in the thermal  
134 cycler for five min. 10  $\mu$ l of Klenow mix (1.0  $\mu$ l 10x Klenow buffer (Promega UK), 8.7  $\mu$ l  
135 water, 0.3  $\mu$ l Klenow polymerase (Promega)) was then added. For any DNA already present  
136 in the sample primer extension was effected with 1.0  $\mu$ l Primer A (40 $\mu$ M), 1.0  $\mu$ l 10x Klenow  
137 buffer and variable amounts of water and template (minimum 50ng/ $\mu$ l) to make a total  
138 volume of 10  $\mu$ l. This sample mixture was then heated to 94°C for two min and then allowed  
139 to cool to 10°C in a thermal cycler for five min. The following 5.05  $\mu$ l reaction mix was  
140 added to the sample mixture during its incubation at 10°C: 0.5  $\mu$ l 10x Klenow buffer, 1.5  $\mu$ l  
141 3mM dNTPs, 0.75  $\mu$ l 0.1M DTT, 1.5  $\mu$ l 500  $\mu$ g/ml BSA, 0.3  $\mu$ l Klenow polymerase  
142 (Promega UK), 0.5  $\mu$ l water. The reaction was left at room temperature for five min,  
143 followed by one minute on ice. The mix was then heated to 94 °C for two min, and rapidly  
144 cooled to 10°C in the thermal cycler for five min. 10  $\mu$ l of Klenow mix (1.0  $\mu$ l 10x Klenow  
145 buffer, 8.7  $\mu$ l water, 0.3  $\mu$ l Klenow polymerase) was then added.  
146 For both RNA and DNA sequence-independent steps the mixture was then heated to 37°C for  
147 8 min, and then held at 37°C for a further 8 min. This was followed by a rapid increase to  
148 94°C for two min after which the mix was cooled to 10°C for five min, during which 1.2  $\mu$ l  
149 of diluted Klenow (1:4) was added. The temperature was again increased to 37°C for 8 min  
150 followed by a hold of 8 min at 37°C, and then the reaction was terminated by placing the  
151 mixture on ice for 5 min. Standard PCR was then conducted using Primer B (GTT TCC  
152 CAG TCA CGA TC) (100  $\mu$ M) to amplify the round A product with the following cycle  
153 parameters one step at 95°C for 10 s; 35 cycles of 30 s at 94°C, 30 s at 40°C, 30 s at 50°C, 2  
154 min at 72°C and one final extension step of 72°C for 2 min. A 50  $\mu$ l reaction mix was

155 prepared from the following: 39.0  $\mu$ l water, 1.5  $\mu$ l 50mM Magnesium chloride ( $MgCl_2$ )  
156 (Invitrogen UK), 5.0  $\mu$ l 10x Mg-free buffer (Invitrogen UK), 0.5  $\mu$ l 25mM dNTP mix, 0.5  $\mu$ l  
157 Primer B, 0.5  $\mu$ l *Taq* polymerase (5 U/ $\mu$ l) (Invitrogen UK) and 3.0  $\mu$ l Round A product.

#### 158 2.1.3.2. Sequence-specific amplification

159 Sequence-specific PCR was performed using a 50- $\mu$ l reaction containing 37.5  $\mu$ l of nuclease-  
160 free water, 2.0  $\mu$ l of 50mM  $MgCl_2$  (Invitrogen UK), 5.0  $\mu$ l of 10x Mg-free Buffer (Invitrogen  
161 UK), 1.0  $\mu$ l of 25mM dNTP mix, 1.0  $\mu$ l of 10 $\mu$ M forward primer, 1.0  $\mu$ l of 10 $\mu$ M reverse  
162 primer, 0.5  $\mu$ l of *Taq* DNA polymerase (5 U/ $\mu$ l) and 2.0  $\mu$ l of cDNA or DNA (optimal  
163 concentration 50ng/ $\mu$ l). Cycling parameters were one step of 94°C for 2 min; 30 cycles of 30  
164 s at 94°C, 1 min at 60°C and 1 min at 72°C and one final extension step of 10 min at 72°C.

165 In addition the Qiagen Multiplex PCR *Plus* kit was tested with the sequence-dependent  
166 primer sets. This was carried out with both non-biotinylated and biotinylated primers.

167 Multiplex PCR was performed using a 50- $\mu$ l reaction containing 25  $\mu$ l Multiplex Master Mix,  
168 5  $\mu$ l 10 x primer mix (2 $\mu$ M each primer) and variable volumes of water and template (50  
169 ng/ $\mu$ l). The recommended protocol in the Qiagen Multiplex PCR *Plus* handbook was  
170 followed with cycling parameters of one step at 95°C for 5 min; 40 cycles of 30 s at 95°C, 90  
171 s at 60°C and 90 s at 72°C and one final extension step of 10 min at 68°C.

172 Real-time PCR was carried out using the Applied Biosystems 7500 Fast Real-Time PCR  
173 System. Real-time PCR was performed using a 10- $\mu$ l reaction containing 5  $\mu$ l of TaqMan®  
174 Universal PCR Master Mix 2x (Life Technologies), 1  $\mu$ l of 300nM forward primer, 1  $\mu$ l of  
175 300 nM reverse primer, 1  $\mu$ l TaqMan® probe (2.5 $\mu$ M), 1  $\mu$ l of nuclease-free water and 1  $\mu$ l  
176 of sample (or water as a negative control). The recommended protocol was followed with  
177 cycling parameters of one step at 50°C for two min, another step at 95°C for 10 min; 40  
178 cycles of 95°C for 15s and 60°C for 60 s. Each sample was run in triplicate.

#### 179 2.1.4. Microarray hybridisation



180 Prior to hybridisation of the labelled sample onto the array, the AS was conditioned by  
181 washing with 150 µl of water for 20 min at 30°C. After the water was removed using a  
182 pipette, a pre-hybridisation buffer (5x saline-sodium citrate (SSC), 0.1% sodium dodecyl  
183 sulphate (SDS), 4x Denhardt's solution) was pipetted into each well for 30 min at 50°C.  
184 Both washes were performed using a thermomixer (BioShake iQ, QUANTIFOIL Instruments  
185 GmbH, Jena Germany) at 550 rpm, which was used in all subsequent incubation steps unless  
186 otherwise stated. A 10-µl aliquot of the biotin-labelled sample was added to 90 µl of  
187 hybridisation buffer (5x SSC, 1% SDS, 4x Denhardt's solution). The mixture was denatured  
188 at 95°C for 3 min and then kept on ice. The denatured sample (100 µl) was then pipetted into  
189 the AS well and allowed to hybridise for 30 min at 55°C at 550 rpm. The sample solution  
190 was then removed and the AS was washed successively for 20 min at 60°C at 550 rpm with  
191 150 µl wash buffer 1 (1x SSC, 0.2% SDS), wash buffer 2 (0.1x SSC, 0.2% SDS), and wash  
192 buffer 3 (0.1x SSC). This buffer was then removed and vacant binding sites on the  
193 microarray were blocked by incubation with a blocking solution (100 µl) of 2% biotin-free  
194 milk in PBS containing 1% bovine serum albumin (BSA) and 0.1% Tween™ 20 for 60 min at  
195 30°C at 300 rpm. The blocking solution was replaced with 100 µl conjugation solution  
196 (Streptavidin Poly-Horseradish peroxidase (HRP) diluted 1:100 in the blocking solution), and  
197 the array incubated for 15 min at 30°C at 300 rpm. Post-conjugation washes were performed  
198 using wash buffers 1-3 as described for the post-hybridisation washes. After removal of  
199 wash buffer 3, 100 µl of a tetramethylbenzidine (TMB)-hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) solution,  
200 in this instance TrueBlue™ (Insight BioTechnology LTD, UK), was added and incubated for  
201 10 min at 25°C without shaking. After removing the solution, the AS was then inserted into  
202 the ArrayMate and the array image was recorded with raw data generated. The recorded  
203 image was analysed using Alere's integrated IconoClust software and analysis script.  
204 Iconoclust processes the signals and automatically normalises the signal value after an

205 algorithm processes the average intensity of the spot and the local background noise. The  
206 output range of the signals was between 0 and 1, with 0 being negative and 1 being the  
207 maximal possible signal value. The normalised intensity of the spots was automatically  
208 calculated by subtracting the local background noise from the average intensity of the  
209 automatically recognised spot.

### 210 3.1. Results

#### 211 3.1.1. PCR amplification and hybridisation

212 A 327 probe ArrayStrip was produced, and the number of probes per pathogen are given in  
213 Table 3. During the evaluation stage, it was determined that sequence-independent  
214 amplification resulted in lower hybridisation signals on the array than sequence-dependent  
215 amplification. Some of the pathogens (e.g. Cowpox, *T. gondii* and *C. jejuni*), when amplified  
216 by their specific primers produced good quality, detectable, hybridisation signals, but when  
217 random amplification was used, they showed no or weak hybridisation. A DNA sample of *C.*  
218 *jejuni* for example was amplified using sequence-independent PCR and the product was then  
219 hybridised onto the array. A measurable signal was seen with 26.6% of the *C. jejuni* probes  
220 on the array. With specific amplification there was 100% probe hybridisation at significantly  
221 higher signal strength (data not shown).

222 Table 3.

223 The number of probes for each pathogen that were spotted on the WT\_Rodent\_Chip\_03  
224 ArrayStrip

225

226 Figures 1A-1H show the images recorded after hybridisation with a variety of *Salmonella*  
227 species following sequence-dependent and sequence-independent amplification. The spots  
228 indicated by arrows are the biotin markers, which act as assay controls. Numerous probes  
229 showed cross-hybridisation in these images, albeit at low signal intensities, so they were

230 removed from the final version of the array. It is also apparent that the cross-hybridising  
231 probes were only visible in the images which show samples that had been amplified using  
232 sequence independent-amplification (Figures 1A-1F). The images which show hybridisation  
233 following sequence-specific amplification were much cleaner (Figures 1G-1H), and had the  
234 expected hybridisation profile. The three spots indicated by the rectangular box in all images  
235 except Figure 1G are probes that were designed to hybridise with a wide range of *Salmonella*  
236 species. Figure 1H shows the amplification of *S. Typhimurium* with a set of primers  
237 designed to amplify this region which is common to multiple *Salmonella* species. *S.*  
238 *Gallinarum* (Figure 1A), *S. Dublin* (Figure 1B), *S. Pullorum* (Figure 1C), *S. Enteritidis*  
239 (Figure 1D), *S. Hadar* (Figure 1E), and *S. Typhimurium* (Figures 1F-1H) were tested on the  
240 array. Although it was visible on the array, the signal strength is low in comparison to Figure  
241 1H. This is particularly noticeable for *S. Dublin* and *S. Hadar* from Figures 1B and 1E.

242 Both sequence-independent and sequence-specific amplification were used for *S.*  
243 *Typhimurium*. The images produced after hybridisation can be seen in Figures 1F and 1G.  
244 Figure 1F shows sequence-independent amplification, and the circled probes were designed  
245 to be specific for *S. Typhimurium*. This set of probes did not show any detectable  
246 hybridisation in the other images so it appeared these were good probes for distinguishing *S.*  
247 *Typhimurium* from other *Salmonella* species. Figure 1G shows the sequence-specific  
248 amplification with a set of primers designed to amplify the *S. Typhimurium*-specific region.  
249 The probes for all of the pathogens tested which produced a hybridisation signal can be seen  
250 in Table A.1 in the Appendix.

251

252 Figure 1.

253 Images produced after hybridisation of various *Salmonella* species on WT\_Rodents\_2\_1.0  
254 array. The spots indicated by arrows are the biotin markers. The solid square and rectangular  
255 areas are the orientation markers.

- 256 A. *S. Gallinarum* hybridisation following random amplification
- 257 B. *S. Dublin* hybridisation following random amplification
- 258 C. *S. Pullorum* hybridisation following random amplification
- 259 D. *S. Enteritidis* hybridisation following random amplification
- 260 E. *S. Hadar* hybridisation following random amplification
- 261 F. *S. Typhimurium* amplification following random amplification
- 262 G. *S. Typhimurium* amplification with primers Salm/flag/1366055/F and  
263 Salm/flag/1366482/R (*S. Typhimurium*-specific)
- 264 H. *S. Typhimurium* amplification with primers Salm/CDP/2167279/F and  
265 Salm/CDP/2005357/R (Generic *Salmonella* species)
- 266

267 Table 4.

268 The negative control sample and reference pathogen samples in lanes 1-12 from Figure 2A.

269

### 270 3.1.2. Multiplex PCR amplification and hybridisation

271 The primer sets which performed well in singleplex PCR reactions were then tested in a  
272 multiplex reaction. As it is unlikely that a sample would contain all of the pathogens tested,  
273 the effectiveness of the primer mix in detecting a pathogen was tested using a sample of  
274 rodent liver DNA which was spiked with individual pathogen DNA (DNA concentration  
275 ranged from 1.66 – 112.5 ng/ $\mu$ L, and copy number from  $2.33 \times 10^9$  –  $2.09 \times 10^{11}$ ). Figure 2A  
276 shows a gel image of the result of amplification of individual pathogens from the spiked  
277 material when the multi-pathogen primer mix was used. Table 4 shows the pathogen  
278 detected in each lane from Figure 2A. As can be seen from the figure, the majority of lanes  
279 had a strong band. The two bands in Lane 9 represent the specific *S. Typhimurium*  
280 amplicons (663 bp) and the generic *Salmonella* amplicons (428 bp). This was expected, as  
281 the multi-pathogen primer mix had primers specific for *S. Typhimurium*, and also had  
282 primers to amplify a region common to many *Salmonella* species. Figure 2B shows the spots

283 that hybridised after using the multiplex primer mix (with biotinylated primers) on a pooled  
284 nucleic acid sample from all pathogens for which reference samples were available.  
285 Although the band seen in Lane 12 for *T. gondii* was quite faint, careful analysis of the  
286 recorded image indicated that all of the pathogens in the sample, including *T. gondii*,  
287 hybridised with the expected specific probes on the array.

288 Figure 2.

289 A. Agarose gel electrophoresis image produced after amplification of nucleic acid of  
290 individual pathogens using the multiplex primer mix.

291 B. Profile produced after hybridisation of a mixture of all the pathogens following  
292 amplification with the multiplex primer mix for which reference samples were available.

### 293 3.1.3. Array sensitivity testing

294 The sensitivity of the array was tested by performing real-time PCR using serially diluted *Y.*  
295 *pestis* DNA. The pathogenic DNA in the sample was no longer detectable using real-time  
296 PCR (Figure 3) at copy numbers less than  $4.39 \times 10^2$ . As expected, there was no  
297 amplification for the negative control sample. Samples in Figure 3B, C, D and E (copy  
298 number  $3.47 \times 10^9$ ,  $1.76 \times 10^7$ ,  $8.57 \times 10^4$ ,  $4.39 \times 10^2$ ) were detectable by real-time PCR. The  
299 DNA in sample B was detectable after 18 cycles. For samples C, D, and E the cycle number  
300 at which detection occurred was 24, 32 and 36, respectively. The DNA in sample F appeared  
301 to have been too low for real-time PCR to detect and no amplification was observed.

302 The array images shown in Figure 3 were produced after hybridisation of the products of  
303 standard PCR amplification. These were the same samples that were tested by real-time PCR  
304 for *Y. pestis* on the *Yersinia\_01* ArrayTube. The biotin markers on each array are indicated  
305 with an arrow. On the *Yersinia\_01* array only two probes were expected to hybridise with  
306 the primer set used (*Y.pes/pPCP/8374/F* *Y.pes/pPCP/8902/R*). As can be seen from the  
307 images produced after hybridisation, the two expected probes hybridised with samples B, C  
308 and D. For samples E and F there was no apparent hybridisation.

309 Figure 3.  
310 Real-time PCR sensitivity testing was performed with serial dilutions of *Y. pestis*. Sample A  
311 was a negative control sample (water). The copy number in samples B to F was  $3.47 \times 10^9$ ,  
312  $1.76 \times 10^7$ ,  $8.57 \times 10^4$ ,  $4.39 \times 10^2$ , and 1. Array images after hybridisation of the standard PCR  
313 products from the same *Y. pestis* amplification on WT\_Yersinia\_01 are also shown. Biotin  
314 markers are indicated by arrows, and *Y. pestis* probes that showed hybridisation are circled.

#### 315 4.1. Discussion

316 Collecting good quality samples for disease surveillance can often be a time and cost  
317 intensive process. Therefore, it is important that any technology used is as efficient as  
318 possible. We report the development of a DNA microarray for simultaneous detection of  
319 multiple pathogens of rodents, comprised of 327 probes derived from a variety of genes in  
320 each of the target pathogens. The technology presented here represents a simple but effective  
321 system which is affordable and compatible with standard laboratory equipment, and has been  
322 used for a variety of purposes over recent years [1, 14-18].

323 The design of oligonucleotide probes is a complex process for a variety of reasons, including  
324 identifying the best target sequences to be screened and understanding the thermodynamics of  
325 probe-target interactions during hybridisation [19]. An oligonucleotide length of 60 bp was  
326 selected, as several studies have indicated that this offers the best combination between  
327 specificity and sensitivity [20-22]. Shorter oligonucleotide probes (15-25 mers) have a very  
328 high specificity, but they have been criticised for having a lack of sensitivity, whereas longer  
329 oligonucleotides (40-90 mers) are thought to have a good sensitivity whilst maintaining a  
330 high specificity [19]. It has been reported that 60-mer oligonucleotides have an eight-fold  
331 higher sensitivity than 25-mers [23].

332 Variation within microarray experiments can still occur regardless of careful probe design.  
333 The typical sources of variation can be broadly divided into three main categories: variation  
334 within the biological sample, the performance of the technology itself, and finally, variation  
335 in the spot signal measurements. The majority of variance in microarray experiments is  
336 generally biological rather than technical [24]. Arrays are generally made in batches and  
337 variation can occur between batches. These can include different probe concentrations,  
338 which can lead to incorrect conclusions being drawn from data [25]. Variation at the array

339 production stage can occur for a number of reasons including, for example the particular  
340 printing pin used, the humidity, and temperature during printing. These variables can lead to  
341 slight differences in the amount of probe that is deposited on the slide surface, the amount  
342 that remains on the array surface after processing, and the level of deviation from the  
343 expected spot location. All of these factors can have an impact on the amount of labelled  
344 target that can bind to the probe, and on the efficiency of subsequent spot finding and data  
345 extraction steps [19]. The level of deviation from the expected location can result in the array  
346 reader making inaccurate readings, the signals of neighbouring probes becoming merged, or  
347 the spot can become invalid and cannot be accurately detected by the analysis software. In  
348 order to reduce the variability that is inherent in all biological experiments, experimental  
349 replication is essential. One obvious form of technical replication is through array probe  
350 replication. It is advantageous to at least have duplicates, or preferably multiples, of all  
351 probes spotted on the same array, however this may not be possible due to spotting density  
352 constraints. The precision of particular probe measurements will be more reliable if the spot  
353 intensities of the replicate spots are averaged for each sample [26].

354 To achieve an efficient hybridisation step, it is important to have probes with a narrow  
355 melting temperature distribution, because the hybridisation step takes place at the same  
356 temperature for all probes on the array [27]. The algorithms used in both OligoWiz and UPS  
357 are able to make minor adjustments to the length of each probe so that a narrow melting  
358 temperature range is achieved. Determination of melting temperature thresholds is a difficult  
359 task as this determines the conditions under which probes will bind to the target sequence.  
360 Melting temperatures can cause loss of signal if too high, and non-specific signal if too low  
361 [28]. As a single temperature is used during the hybridisation step, it is advisable that the  
362 narrowest melting temperature range be used to maximise signal detection [29].



363 The chip presented here represents a prototype microarray identification system for zoonotic  
364 pathogens that can infect rodents. The probes used on the microarray were based on genes  
365 that are unique to the pathogens selected. These genes were selected following a literature  
366 search to identify gene sequences which have been previously used to identify these  
367 pathogens, and a BLAST analysis to see if the sequences selected had similarity to any other  
368 pathogen sequences on the database. This is also the first report of biotinylated primers used  
369 in a multiplex format with up to 24 primer pairs. There was no apparent difference in the  
370 hybridisation signal produced when only a single pathogen was present in single and  
371 multiplex PCR reactions. More work needs to be done to determine the limits of detection  
372 and the sensitivity of the array, but as a proof of concept the array has demonstrated potential.  
373 Further improvements to this array could be made by obtaining reference material for  
374 pathogens which were unavailable and evaluating the probes for these pathogens. Whilst  
375 reference material was available for SEOV during the evaluation stage, several attempts at  
376 PCR proved unsuccessful. However, a number of rodent samples (nucleic acid was extracted  
377 from liver, kidney and lung of *R. rattus* and *R. norvegicus*, an aliquot of which was then  
378 pooled and amplified by multiplex PCR followed by hybridisation with the microarray) were  
379 screened on the array and two of these were identified as SEOV positive. This was later  
380 verified by both PCR and sequencing.

381 While *in silico* analysis of the gene and resulting probe sequences are important in  
382 eliminating the possibility of cross-hybridisation with other sequences already on the NCBI  
383 database, it does not rule out the possibility of cross-hybridisation with newly emerging  
384 organisms for which the gene sequence is unknown. As a result, microarrays can be used to  
385 identify novel as well as known pathogens. This can be achieved by designing probes at a  
386 genus level with additional probes designed for differentiating between species [30].

387 The presence of host nucleic acid in a sample presents another challenge in microarray  
388 experiments, as it can lower the sensitivity of the array. This occurs because in most  
389 situations the host DNA is present in much higher amounts than the pathogen nucleic acid,  
390 which makes the pathogen more difficult to detect. The sensitivity of an array may be  
391 improved by the removal of host nucleic acid by DNAses, i.e. enriching pathogen-derived  
392 nucleic acid, using dedicated methods and kits for this purpose prior to PCR amplification  
393 [31]. The sensitivity on this array was less than that of real-time PCR, as has been previously  
394 demonstrated with other pathogen detecting microarrays [14, 32], this leads to a trade-off  
395 between sensitivity and cost-effectiveness. It would have been useful to have tested the array  
396 sensitivity for RNA pathogens as well. However, as mentioned earlier, there were no  
397 working RNA pathogens available during the evaluation stage. A critical step in the  
398 development of a microarray is sourcing reference samples with which the array can be  
399 evaluated.

400 The design stage can be the deciding factor in the success of any microarray experiment and  
401 the choice of array platforms or probe types can be challenging. However, it is now  
402 becoming increasingly clear that when a careful design is followed, the results obtained with  
403 different platforms are likely to be comparable [19, 33, 34]. The user can decide whether to  
404 invest time and resources in developing their own arrays, utilise one of the commercial  
405 providers who can assist with array design and fabrication, or use off-the-shelf commercial  
406 arrays. The relatively low cost of screening for many pathogens simultaneously in a single  
407 sample is an economical and efficient approach for rapid and sensitive diagnostics. This may  
408 be of particular use for wildlife samples which may be small in volume and are often  
409 irreplaceable.

410 Acknowledgements

411 This research has received funding from the European Union Seventh Framework  
412 Programme (FP7/2007-2013) under grant agreement n° 222633. We would like to thank  
413 Chelsea Himsworth, Florence Ayrat, and Kieran Pounder for providing the tissue samples.  
414 The authors would also like to thank those who contributed reference samples for the  
415 evaluation stage (Konrad Sachse, Brendan Wren, Karen Kempsall, Zoree Djelouadji, Michael  
416 Jones, Sean McAteer, David Gally, Margaret Lovell, Sylvia Grierson, Nicole Pavio,  
417 Charalambos Bilinis, Fimme van der Wal, Public Health England and the European Virus  
418 Archive).

419  
420 References

- 421 1. Sachse, K., et al., *DNA microarray-based detection and identification of Chlamydia*  
422 *and Chlamydophila spp.* Molecular and Cellular Probes, 2005. **19**(1): p. 41-50.
- 423 2. Taylor, L.H., S.M. Latham, and M.E.J. Woolhouse, *Philosophical Transactions of the*  
424 *Royal Society of London, Series B, Biological Sciences.* The Royal Society, 2001.  
425 **356**(1411): p. 983-989.
- 426 3. Russell, L.B., *Is Prevention better than Cure?* 1986, Washington D.C.: The  
427 Brookings Institution.
- 428 4. Dong, J., et al., *Emerging Pathogens: Challenges and Successes of Molecular*  
429 *Diagnostics.* Journal of Molecular Diagnostics, 2008. **10**(3): p. 185-197.
- 430 5. Wang, D., et al., *Viral Discovery and Sequence Recovery Using DNA Microarrays.*  
431 PLoS Biology, 2003. **1**(2): p. e2.
- 432 6. Wang, L.C., et al., *Simultaneous detection and differentiation of Newcastle disease*  
433 *and avian influenza viruses using oligonucleotide microarrays.* Veterinary  
434 Microbiology, 2008. **127**: p. 217-226.
- 435 7. Jack, P.J.M., et al., *Microarray-based detection of viruses causing vesicular or*  
436 *vesicular-like lesions in livestock animals.* Veterinary Microbiology, 2009. **133**: p.  
437 145-153.
- 438 8. Ehricht, R., et al., *Optimized DNA microarray assay allowss detection and genotyping*  
439 *of single PCR-amplifiable target copies.* Molecular and Cellular Probes, 2006. **20**(1):  
440 p. 60-63.
- 441 9. Müller, R., et al., *Detection of herpesvirus and adenovirus co-infections with*  
442 *diagnostic DNA-microarrays.* Journal of Virological methods, 2009. **155**(2): p. 161-  
443 166.
- 444 10. Chen, S.H., et al., *UPS 2.0: unique probe selector for probe design and*  
445 *oligonucleotide microarrays at the pangenomic/genomic level.* BMC Genomics,  
446 2010. **11**(4).
- 447 11. Wernersson, R. and H.B. Nielsen, *OligoWiz 2.0 - integrating sequence feature*  
448 *annotation into the design of microarray probes.* Nucleic Acids Research, 2005. **33**:  
449 p. 611-615.
- 450 12. Wernersson, R., A.S. Juncker, and H.B. Nielsen, *Probe selection for DNA*  
451 *microarrays using OligoWiz.* Nature Protocols, 2007. **2**(11): p. 2677-2691.  
452

- 453 13. Bohlander, S.K., et al., *A method for the rapid sequence-independent amplification of*  
454 *microdissected chromosomal material*. Genomics, 1992. **13**(4): p. 1322-1324.
- 455 14. Dean, D., et al., *Zoonotic Chlamydiaceae Species Associated with Trachoma, Nepal*.  
456 *Emerging Infectious Diseases*, 2013. **19**(12): p. 1948-1955.
- 457 15. Ehricht, R., et al., *Optimised DNA Microarray assay allows detection and genotyping*  
458 *of single PCR-amplifiable target copies*. Molecular and Cellular Probes, 2006. **20**: p.  
459 60-63.
- 460 16. Ruettinger, A., et al., *Genotyping of Chlamydia trachomatis strains from culture and*  
461 *clinical samples using an ompA-based DNA microarray assay*. Molecular and  
462 *Cellular Probes*, 2011. **25**(1): p. 19-27.
- 463 17. Ruettinger, A., et al., *Rapid Spoligotyping of Mycobacterium tuberculosis Complex*  
464 *Bacteria by Use of a Microarray System with Automatic Data Processing and*  
465 *Assignment*. Journal of Clinical Microbiology, 2012. **50**(7): p. 2492-2495.
- 466 18. Sachse, K., et al., *More than classical Chlamydia psittaci in urban pigeons*.  
467 *Veterinary Microbiology*, 2012. **157**(3-4): p. 476-480.
- 468 19. Russell, S., K.A. Meadows, and R.R. Russel, *Microarray Technology in Practice*.  
469 2009, Cambridge: Academic Press.
- 470 20. Religio, A., et al., *Optimisation of oligonucleotide-based DNA microarrays*. Nucleic  
471 *Acids Research*, 2002. **30**(e51).
- 472 21. Kane, M.D., et al., *Assessment of the sensitivity and specificity of oligonucleotide*  
473 *(50mer) microarrays*. Nucleic Acids Research, 2000. **28**: p. 4552-4557.
- 474 22. Wang, H.Y., et al., *Assessing unmodified 70-mer oligonucleotide probe performance*  
475 *on glass-slide microarrays*. Genome Biology, 2003a. **4**(1): p. R5.
- 476 23. Chou, C.C., et al., *Optimisation of probe length and the number of probes per gene*  
477 *for optimal microarray analysis of gene expression*. Nucleic Acids Research, 2004.  
478 **32**(12): p. e99.
- 479 24. Koskinen, M.T., et al., *Analytical specificity and sensitivity of a real-time polymerase*  
480 *chain reaction assay for identification of bovine mastitis pathogens*. Journal of Dairy  
481 *Science*, 2009. **92**(3): p. 952-959.
- 482 25. Leek, J.T., Scharpf, R.B., Bravo, H.C., Simcha, D., Langmead, B., Johnson, W.E.,  
483 Geman, D., Baggerly, K., Irizarry, R.A., *Tackling the widespread and critical impact*  
484 *of batch effects in high-throughput data*. Nature Reviews Genetics, 2010. **11**: p. 733-  
485 739.
- 486 26. Tran, P.H., et al., *Microarray optimisations: increasing spot accuracy and automated*  
487 *identification of true microarray signals*. Nucleic Acids Research, 2002. **30**(12): p.  
488 e54.
- 489 27. Haque, R., et al., *Multiplex real-time PCR assay for detection of Entamoeba*  
490 *histolytica, Giardia intestinalis and Cryptosporidium spp.* The American Journal of  
491 *Tropical Medicine and Hygiene*, 2007. **76**(4): p. 713-717.
- 492 28. Blalock, E., *A Beginner's Guide to Microarrays*, ed. E. Blalock. 2003, Norwell,  
493 Massachusetts: Kluwer Academic Publishers.
- 494 29. Lemoine, S., F. Combes, and S. Le Crom, *An evaluation of custom microarray*  
495 *applications: the oligonucleotide design challenge*. Nucleic Acids Research, 2009.  
496 **37**(6): p. 1726-1739.
- 497 30. Wang, D., et al., *Viral Discovery and Sequence Recovery Using DNA Microarrays*.  
498 *Public Library of Science Biology*, 2003. **1**(2): p. 257-260.
- 499 31. Gurrula, R., et al., *Development of a DNA microarray for simultaneous detection and*  
500 *genotyping of lyssaviruses*. Virus Research, 2009. **144**(1-2): p. 202-208.

- 501 32. Borel, N., et al., *Direct identification of chlamydiae from clinical samples using a*  
502 *DNA microarray assay-A validation study*. *Molecular and Cellular Probes*, 2008.  
503 **22**(1): p. 55-64.
- 504 33. Jarvinen, A.K., et al., *Are data from different gene expression microarray platforms*  
505 *comparable?* *Genomics*, 2004. **83**(6): p. 1164-1168.
- 506 34. Irizarry, R.A., et al., *Multiple-laboratory comparison of microarray platforms*. *Nature*  
507 *Methods*, 2005. **2**: p. 345-350.

508

509